Ricolinostat
Cat. No.：YN270334
CAS No. ：1316214-52-4
| 产品名称: | Ricolinostat |
| CAS No.: | 1316214-52-4 |
| Chemical Name: | 2-(diphenylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]-5-pyrimidinecarboxamide |
| Synonyms: | ACY-1215; Rocilinostat |
| 分子量: | 433.50 |
| 分子式: | C₂₄H₂₇N₅O₃ |
| SMILES: | O=C(C1=CN=C(N(C2=CC=CC=C2)C3=CC=CC=C3)N=C1)NCCCCCCC(NO)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Ricolinostat (ACY-1215) 是一种有效，选择性的HDAC6抑制剂，IC50为 5 nM。ACY-1215 也可抑制HDAC1，HDAC2和HDAC3，IC50分别为 58，48 和 51 nM。 |
| IC50和靶点: | [{name:"HDAC6:4.7 nM (IC50)"},{name: "HDAC2:48 nM (IC50)"},{name: "HDAC3:51 nM (IC50)"},{name: "HDAC1:58 nM (IC50)"},{name: "HDAC8:100 nM (IC50)"},{name: "HDAC7:1400 nM (IC50)"},{name: "HDAC5:5000 nM (IC50)"},{name: "HDAC4:7000 nM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Santo, L., Hideshima, T., Kung, A.L., et al.Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaBlood119(11),2579-2589(2012)
Amengual, J.E., Johannet, P., Lombardo, M., et al.Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphomaClin. Cancer Res.21(20),4663-4675(2015)
Gradilone, S.A., Habringer, S., Masyuk, T.V., et al.HDAC6 is overexpressed in cystic cholangiocytes and its inhibition reduces cystogenesisAm. J. Pathol.184(3),600-608(2014)
